neuroptika

to protect sight & prevent vision loss

about

Clear-Sighted Vision for Retinal Health

Singular focus on patients with a dedicated scientific team leading ophthalmology research

Executive Team

Tim Min (민현석), MA, JD

CO-CEO

Tim has more than 20 years of experience as biotech and pharmaceutical researcher, lawyer and entrepreneur with a focus on cutting edge science and intellectual property.

LinkedIn

Taeksang Park (박택상), CPA

CO-CEO

Taeksang brings more than 23 years of corporate finance, M&A, IPO and strategic planning from Korean conglomerate to successfully launched biotech entities.

LinkedIn

technology

Protecting your visual Path - Innovative Treatment for Optimal Retinal Health
Focus on Retinal Degeneration from early intervention and protection through the entire visual pathway
Why is a healthy retina important to your vision?  
The retina is a thin layer of tissue that lines the back of the eye and contains specialized cells called photoreceptors that convert light into electrical signals that can be interpreted by the brain.  The retina is a crucial component of the visual system, and a healthy retina is essential for good vision for several reasons.  The retina is responsible for processing visual information and sending it to the brain via the optic nerve.  Damage to the retina can result in vision loss or distortion, such as blind spots or wavy lines.

Growing Glaucoma & AMD Patients & Their Unmet Needs
Glaucoma is a complex and progressive eye disease that can cause irreversible damage to the optic nerve and result in vision loss if left untreated.  While current treatments for glaucoma can lower eye pressure and slow the progression of the disease, they do not necessarily protect the optic nerve from damage.  There is a need for neuroprotective therapies that can prevent or repair damage to the optic nerve and improve visual outcomes. The prevalence of glaucoma, or the proportion of the population with the disease, is increasing globally as the population ages. According to the World Health Organization (WHO), it is estimated that approximately 80 million people worldwide will have glaucoma by 2020, with that number expected to increase to 111.8 million by 2040.

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, the central part of the retina responsible for sharp, central vision.While there are some treatments available for AMD, there are still some unmet needs in the field of AMD treatment.  Dry AMD, the most common form of the disease, has no approved treatment options.  While some treatments can slow the progression of wet AMD, there are currently no treatments that can reverse the damage caused by dry AMD.  There is a need for more effective treatments for this form of the disease.According to the World Health Organization (WHO), it is estimated that approximately 196million people worldwide will have AMD by 2020, with that number expected to increase to 288 million by 2040.

Glaucoma

NRO-CMK is targeting to treat Neurodegenerative glaucoma, also known as normal-tension glaucoma or low-tension glaucoma, is a type of glaucoma where damage to the optic nerve occurs despite normal intraocular pressure (IOP). Typically, glaucoma is associated with elevated IOP, which puts pressure on the optic nerve and causes damage over time. However, in neurodegenerative glaucoma, optic nerve damage and vision loss happen even though the IOP remains within the normal range.
We identified a target that can protect most of all retinal ganglion cells in disease models.  This target preserve the function and survival of neurons in the retina, which can help to maintain vision and prevent further vision loss.  Neuroprotection could potentially slow down or stop the progression of these diseases such as glaucoma and age-related macular degeneration.

Dry AMD

NRO-VTN is targeting drusen to treat Dry age-related macular degeneration (dry AMD) is a common eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. AMD is a progressive disease, and the dry form is the most common type, accounting for about 80-90% of all AMD cases. In dry AMD, small yellow deposits called drusen accumulate beneath the macula. These deposits can cause the macula to thin and dry out, leading to gradual loss of central vision.
Our molecule inhibits the early prevention of drusen formation to reduce the risk of developing AMD, preserve vision, and potentially lead to cost savings and improved understanding and treatment of the disease.  Large drusen are a known risk factor for AMD, and the presence of these deposits can increase the likelihood of developing the disease.  Preventing or reducing the formation of drusen may help to lower the risk of developing AMD.

Wet AMD & DR

We are working on a Wet age-related macular degeneration (wet AMD) which is an advanced form of AMD, a progressive eye disease that affects the macula, the central part of the retina responsible for sharp, central vision. Unlike the dry form of AMD, which involves the accumulation of drusen (yellow deposits) beneath the macula, wet AMD is characterized by the growth of abnormal blood vessels beneath the macula.

pipelines

Journey into Retinal Health with Novel Pipelines -
We’ve launched new approaches to treating retinal diseases
preclinical

NRO-CMK

We are delivering Calcium/calmodulin-dependent protein kinase II (CaMKII) via singleAAV intravitreal injection to protect retinal ganglion cells (RGC).  Our animal model showed that CaMKII plays a crucial role in RGC survival and function. CaMKII is involved in the regulation of axonal growth and guidance, synaptic plasticity, and cell survival. It is also implicated in the pathogenesis of various retinal diseases, including glaucoma and retinal ischemia.

PRECLINICAL

NRO-VTN

We are inhibiting the surface exposed functional domain of vitronectin by delivering an antibody.  In AMD patients, VTN levels were elevated and it plays an essential role in the drusen formation.  VTN interacts with several other molecules that are involved in AMD pathogenesis, including complement factor H (CFH) and complement factor I (CFI).

preclinical

undisclosed

We are currently working on a novel target to treat patients suffering from diabetic retinopathy and diabetic macular edema.

news & updates

July 11, 2022

Neuroptika obtains exclusive agreement from Icahn School of Medicine at Mount Sinai

Neuroptika today announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease.

read more
October 31, 2021

Neuroptika receives final CSR of Phase 2 Clinical Trial in Japan

Neuroptika today announced completion of Phase 2 trial in Japan for Dry Eye Disease

read more
September 24, 2021

Neuroptika relocates to Korea and Taeksang Park joins are co-CEO

Neuroptika today announced completion of Phase 2 trial in Japan for Dry Eye Disease

read more
July 19, 2021

Neuroptika obtains option to exclusive license from Sanford Burnham Prebys

Neuroptika today announced completion of Phase 2 trial in Japan for Dry Eye Disease

read more
August 17, 2020

Neuroptika Completes Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Neuroptika today announced completion of enrollment in a Phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease.

read more
April 30, 2019

Neuroptika Announces Positive Data from NRO-1 Phase 1 Clinical Trial

Neuroptika today announced positive data from the company's Phase 1 clinical trial to determine the safety, tolerability, and pharmacokinetics of topical NRO-1 in healthy subjects.

read more
January 16, 2019

Neuroptika Announces Enrollment of First Patient In Phase 2 Clinical Trial for Dry Eye Disease

Neuroptika today announced that the first patient was enrolled in a Phase 2 clinical trial of NRO-1 for the treatment of dry eye disease.

read more
December 25, 2018

Neuroptika Launches to Develop Novel Regenerative Treatment

Neuroptika today announced its initiation as a company to develop a novel therapeutic drug to protect and regenerate corneal nerves in ophthalmic diseases.

read more

partners & investors

2024 Neuroptika Inc. All Rights reserved.